检索结果-南通市图书馆

Real world effectiveness of PCSK-9 inhibitors combined with statins versus statins-based therapy among patients with very high risk of atherosclerotic cardiovascular disease in China(RWE-PCSK study)

在线全文

学校读者我要写书评

暂无评论

Journal of Geriatric Cardiology 2021年第4期18卷 261-270页

作者： yu-Qi liu Dan-Dan li Meng CHAI Hong-liang CONG xiao-Qiang CONG Jun DAI Rong-Pin DU ming GAO Jin-cheng GUO Yan-qing GUO xiao-Jian HONG Rong-Chong HUANG feng-Shun JIA Jia-yu li qing li Jia-Mei liu Xin-ping liu yu-Guo liu Hong-Gang NIE Bing SHAO xiao-yu SHEN Hai-qing SONG yi-Jun SONG li-Jun wang Shuo wang dong-Mei WU Jing XIA Zhi-Yong YANG Hong-ying yu Hui ZHANG Tie-Mei ZHANG Ji-yi ZHAO liang-chen ZHAO ming-Qi ZHENG yun-Dai chen Department of Cardiology Chinese PLA General HospitalBeijingChina Department of Cardiology Beijing Anzhen HospitalCapital Medical UniversityBeijing Institute of Heart Lung and Blood Vessel DiseaseBeijing Key Laboratory of Precision Medicine of Coronary Atherosclerotic DiseaseClinical Center for Coronary Heart DiseaseCapital Medical UniversityBeijingChina Department of Cardiology Tianjin Chest HospitalTianjinChina Department of Cardiology the First Hospital of Jilin UniversityChangchunChina Department of Cardiology Fuwai HospitalNational Center for Cardiovascular DiseaseChinese Academy of Medical Sciences and Peking Union Medical CollegeBeijingChina Department of Cardiology Hebei People’s HospitalShijiazhuangChina Department of Cardiology Kailuan General HospitalHebei Union UniversityTangshanChina Department of Cardiology Beijing Luhe HospitalCapital Medical UniversityBeijingChina Department of Cardiology Shanxi Cardiovascular HospitalTaiyuanChina Department of Cardiology the Fourth Affiliated Hospital of Harbin Medical UniversityHarbinChina Department of Cardiology Beijing Friendship HospitalCapital Medical UniversityBeijingChina Department of Cardiology Tangshan Worker’s HospitalTangshanChina Department of Cardiology China-Japan Friendship Hospital Affiliated Jilin UniversityChangchunChina Department of Cardiology Handan Central HospitalHebeiChina Heart Center Beijing Key Laboratory of HypertensionBeijing Chao-Yang HospitalCapital Medical UniversityBeijingChina Department of Cardiology the First Affiliated Hospital of Dalian Medical UniversityLiaoningChina Department of Cardiology the Second Affiliated Hospital of Harbin Medical UniversityHarbinChina Department of Cardiology the Second Affiliated Hospital of Shenyang Medical CollegeShenyangChina Department of Cardiology the Second Hospital of Shanxi Medical UniversityTaiyuanChina Department of Neurology Xuanwu Hospital Capital Medical UniversityBeijingChina Department of Neurology Tianjin Medical University Gen

BACKGROUND The efficacy and safety of proprotein convertase subtilisin/kexin type 9(PCSK-9) inhibitors were confirmed by several clinical trials, but its effectiveness in routine clinical practice in China has not been evaluated. This study aims to describe the real world effectiveness of PCSK-9 inhibitors combined with statins compared with statins-based therapy among patients with very high risk of atherosclerotic cardiovascular disease(ASCVD).METHODS This is a multi-center observational study, enrolled patients from 32 hospitals who underwent percutaneous coronary intervention(PCI) from January to June in 2019. There are 453 patients treated with PCSK-9 inhibitors combined with statins in PCSK-9 inhibitor group and 2,610 patients treated with statins-based lipid lowering therapies in statins-based group. The lipid control rate and incidence of major adverse cardiovascular events(MACE) over six months were compared between two groups.A propensity score-matched(PSM) analysis was used to balance two groups on confounding factors. survival analysis using Kaplan-Meier methods was applied for *** In a total of 3,063 patients, 89.91% of patients had received moderate or high-intensity statins-based therapy before PCI, but only 9.47% of patients had low-density lipoprotein cholesterol(LDL-C) levels below 1.4 mmol/L at baseline. In the PSM selected patients, LDL-C level was reduced by 42.57% in PCSK-9 inhibitor group and 30.81%(P < 0.001) in statins-based group after six months. The proportion of LDL-C ≤ 1.0 mmol/L increased from 5.29% to 29.26% in PCSK-9 inhibitor group and 0.23% to 6.11% in statins-based group, and the proportion of LDL-C ≤ 1.4 mmol/L increased from 10.36% to 47.69% in PCSK-9 inhibitor group and 2.99% to 18.43% in statins-based group(P < 0.001 for both). There was no significant difference between PCSK-9 inhibitor and statins-based treatment in reducing the risk of MACE(hazard ratio = 2.52, 95% CI: 0.49-12.97, P = 0.250).CONCLUSIONS In the real

关键词： LDL RWE-PCSK study Real world effectiveness of PCSK-9 inhibitors combined with statins versus statins-based therapy among patients with very high r

Expert consensus for pertussis in children: new concepts in diagnosis and treatment

在线全文

学校读者我要写书评

暂无评论

World Journal of Pediatrics 2024年第12期20卷 1209-1222页

作者： yu-Mei mi Ji-Kui Deng Ting Zhang qing Cao Chuan-qing wang Sheng Ye ying-Hu chen Han-qing He Bei-Bei Wu Yan liu Mei Zeng Wei li Fang Wu Hong-Mei Xu Shi-Yong Zhao Gang liu wang Hua Dan Xu Guan-Nan Bai ying Yang li-su Huang yi-ping chen Kai-Hu Yao Zhu-Jun Shao Chun-Zhen Hua Department of Infectious Diseases Children′s HospitalZhejiang University School of MedicineNational Clinical Research Center for Child HealthHangzhou 310052China Department of Infectious Diseases Shenzhen Children′s HospitalShenzhen 518038China Department of Infectious Diseases School of MedicineShanghai Children′s HospitalShanghai Jiao Tong UniversityShanghai 200262China Department of Infectious Diseases Shanghai Children′s Medical CenterShanghai Jiao Tong University School of MedicineShanghai 200127China Department of Nosocomial Infection Control Department of Clinical LaboratoryChildren′s Hospital of Fudan UniversityShanghai 201102China Department of General Intensive Care Medicine Children′s HospitalZhejiang University School of MedicineNational Clinical Research Center for Child HealthHangzhou 310052China Department of Immunization Program Zhejiang Provincial Center for Disease Control and PreventionHangzhou 310052China Department of microbiology Zhejiang Provincial Center for Disease Control and PreventionHangzhou 310052China Department of Immunization Program Hangzhou Center for Disease Control and PreventionHangzhouChina Department of Infectious Diseases Children′s Hospital of Fudan UniversityShanghai 201102China Department of Clinical Laboratory Children′s HospitalZhejiang University School of MedicineNational Clinical Research Center for Child HealthHangzhou 310052ZhejiangChina Department of Chinese Medicine Children′s HospitalZhejiang University School of MedicineNational Clinical Research Center for Child HealthHangzhou 310052China Department of Infectious Diseases Chongqing Children′s HospitalChongqing 400015China Department of Infectious Diseases Hangzhou Children′s HospitalHangzhou 310014China Department of Infectious Diseases Beijing Pediatric Research InstituteNational Center for Children′s HealthBeijing Children′s HospitalCapital Medical UniversityBeijing 100045China Department of Infectious Diseases Yuying Children′s Hospital of Wenzhou Medical Coll

Background Pertussis resurgence has been reported worldwide in the past two decades. Pertussis is still endemic and diffcult to control though with universal vaccination in children. The resurgence may be related to multiple variables, such as increased disease awareness and laboratory tests, waning of immunity following vaccination, and/or genetic mutations of Bordetella pertussis. For better pertussis prevention, diagnosis, and management, we called up an expert panel to develop this expert consensus to provide new concepts in diagnosis and treatment for clinical *** sources The expert groups collected clinical evidence, summarized their clinical experiences, evaluated preliminary recommendations or guidelines, and then organized open-ended discussions to form the recommendations. This consensus was developed by reviewing the literature and studies in databases, including PubMed, Cochrane, EMBASE, the China Biomedical Database, and the Chinese Journal Full-text Database up to May 2024. The search terms included “pertussis” or “whooping cough”, “children”, “diagnosis”, and “treatment”.Results The burden of pertussis has also changed from infants to school children and adults, and these age groups have consequently become the main source of infection for vulnerable population including infants and newborns. In China, a high prevalence of erythromycin-resistant Bordetella pertussis (ERBP) has been reported in the past decade. ERBP may lead to failed clinical empirical treatment with macrolides, which poses a great challenge for pertussis management and control. For better management of pertussis, a fow diagram for diagnosis and treatment of pertussis was presented in this consensus. This consensus also described the diagnostic criteria for pertussis, high-risk cases, and severe pertussis. Macrolides can still be used to treat confrmed erythromycin-sensitive B. pertussis (ESBP) infections, whereas oral trimethoprim–sulfamethoxazole therapy is the initial tr

关键词： Children Diagnosis Expert consensus Pertussis Treatment

Chinese guidelines for the diagnosis and treatment of hand, foot and mouth disease (2018 edition)

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Pediatrics 2018年第5期14卷 437-447页

作者： Xing-wang li Xin Ni su-yun Qian Quan wang Rong-Meng Jiang Wen-Bo Xu yu-Cai Zhang Guang-Jun yu Qiang chen yun-xiao Shang cheng-Song Zhao Hui yu Ting Zhang Gang liu Hui-ling Deng Jie Gao Xian-Gui Ran Qiao-Zhi Yang Bian-li Xu Xue-Yong Huang Xing-dong Wu yi-xiao Bao yi-ping chen Zhi-Hai chen qing-Quan liu Guo-ping Lu Chun-feng liu Rong-Bing wang Guo-liang Zhang Fang Gu Hong-Mei Xu ying li Tao Yang Infectious Disease Diagnosis and Treatment Center Beijing Ditan Hospital Capital Medical UniversityBeijingChina Otorhinolaryngology Head andN eck surgery Beijing Children’s HospitalCapital Medical UniversityBeijingChina Prediatric Intensive Care Unit Beijing Children’s Hospital of Capit al Medical UniversityBeijingChina National Institute For Viral Disease Control and Prevention Chinese Center for Disease Control and Pre ventionBeijingChina Children’s Hospital ofShanghai Jiaotong University ShanghaiChina Pneumology department Jiangxi Provincial Children’s HospitalNanchangChina Department of P ediatric Pneumology Shengjing Hospital of China Medical UniversityShenyangChina Department of Inf ectious Diseases Beijing Children’s HospitalCapital Medical UniversityBeijingChina Department of Inf ectious Diseases Children’s Hospital of Fudan UniversityShanghaiChina Digestive Department Children’s Hospital of Shanghai Jiaotong UniversityShanghaiChina Department of Inf ectious Diseases The Children’s Hospital of Xi'anXi’anChina Infection Control Offi ce Children’s Hospital ofShanghai Jiaotong UniversityShanghaiChina Department ofR espiratory Medicine People’s Hospital ofFuy ang CityFuyangChina Department of P ediatrics People’s Hospital of Liaoc heng CityLiaochengChina

Background Hand, foot, and mouth disease (HFMD) is a common infectious disease in childhood caused by an enterovirus (EV), and which is principally seen in children under 5 years of age. To promote diagnostic awareness and effective treat-ments, to further standardize and strengthen the clinical management and to reduce the mortality of HFMD, the guidelines for diagnosis and treatment have been developed. Methods National Health Commission of China assembled an expert committee for a revision of the guidelines. The com-mittee included 33 members who are specialized in diagnosis and treatment of HFMD. Results Early recognition of severe cases is utmost important in diagnosis and treatment of patients with HFMD. The key to diagnosis and treatment of severe cases lies in the timely and accurate recognition of stages 2 and 3 of HFMD, in order to stop progression to stage 4. Clinicians should particularly pay attention to those EV-A71 cases in children aged less than 3 years, and those with disease duration less than 3 days. The following indicators should alert the clinician of possible deterioration and impending critical disease: (1) persistent hyperthermia;(2) involvement of nervous system;(3) worsening respiratory rate and rhythm;(4) circulatory dysfunction;(5) elevated peripheral WBC count;(6) elevated blood glucose and (7) elevated blood lactic acid. For treatment, most mild cases can be treated as outpatients. Patients should be isolated to avoid cross-infection. Intense treatment modalities should be given for those severe cases. Conclusion The guidelines can provide systematic guidance on the diagnosis and management of HFMD.

关键词： Diagnosis Guidelines HFMD Treatment

Detection of an anti-angina therapeutic module in the effective population treated by a multi-target drug Danhong injection:a randomized trial

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Signal Transduction and Targeted Therapy 2021年第10期6卷 3009-3018页

作者： Jun liu Dan-Dan li Wei dong yu-Qi liu Yang Wu Da-Xuan Tang Fu-Chun Zhang Meng Qiu Qi Hua Jing-yu He Jun li Bai Du Ting-Hai Du lin-lin Niu Xue-Jun Jiang Bo Cui Jiang-Bin chen Yang-Gan wang Hai-Rong wang Qin yu Jing He yi-lin Mao xiao-Fang Bin yue Deng yu-Dan Tian qing-Hua Han Da-Jin liu li-Qin Duan ming-Jun Zhao Cui-ying Zhang Hai-ying Dai Ze-Hua li ying xiao you-Zhi Hu xiao-yu Huang Kun Xing Xin Jiang Chao-feng liu Jing An feng-Chun li Tao Tao Jin-Fa Jiang ying Yang Yao-Rong dong Lei Zhang Guang Fu ying li Shu-Wei Huang li-ping Dou Lan-Jun sun ying-Qiang Zhao Jie li yun Xia Jun liu Fan liu Wen-Jin He ying li Jian-Cong Tan Yang lin Ya-Bin Zhou Jian-Fei Yang Guo-qing Ma Hui-Jun chen He-ping liu Zong-Wu liu Jian-Xiong liu xiao-Jia Luo xiao-Hong Bin Ya-Nan yu Hai-Xia Dang Bing li Fei Teng wang-min Qiao xiao-Long Zhu Bing-Wei chen Qi-Guang chen Chun-Ti Shen Yong-Yan wang yun-Dai chen Zhong wang Institute of Basic Research in Clinical Medicine China Academy of Chinese Medical SciencesBeijingChina Department of Cardiology Chinese PLA General HospitalBeijingChina Department of Cardiology Dongfang Hospital Affiliated to Beijing University of Chinese MedicineBeijingChina Department of Geratology Peking University Third HospitalBeijingChina Department of Cardiology Xuan Wu HospitalCapital Medical UniversityBeijingChina Department of Cardiology Guang'anmen HospitalChina Academy of Chinese Medical SciencesBeijingChina Department of Cardiology First Affiliated Hospital of Henan University of Chinese MedicineZhengzhouHenanChina Department of Cardiology Wuhan University Renmin HospitalWuhanHubeiChina Department of Cardiology Wuhan University Zhongnan HospitalWuhanHubeiChina Affiliated Zhongshan Hospital of Dalian University DalianLiaoningChina Department of Cardiology Second Affiliated Hospital to Hunan University of Chinese MedicineChangshaHunanChina Department of Cardiology First Affiliated Hospital to Changchun University of Chinese MedicineChangchunJilinChina Department of Cardiology First Affiliated Hospital to Shanxi Medical UniversityTaiyuanShanxiChina Department of Cardiology Affiliated Hospital of Shanxi University of Chinese MedicineXianyangShanxiChina Department of Cardiology Changsha Central HospitalChangshaHunanChina Department of Cardiology Hubei Provincial Hospital of Traditional Chinese MedicineWuhanHubeiChina Department of Cardiology Shanxi Provincial People's HospitalXi'anShanxiChina Department of Cardiology Shanxi Province Hospital of Traditional Chinese MedicineXi'anShanxiChina Department of Cardiology Xi'an City Hospital of Traditional Chinese MedicineXi'anShanxiChina Department of Cardiology Shanghai Tongji HospitalShanghaiChina Department of Cardiology Shanghai Municipal Hospital of Traditional Chinese MedicineShanghaiChina Department of Cardiology The First Hospital of ChangshaChangshaHunanChina Department of Cardiology Xinhua Hospi

It's a challenge for detecting the therapeutic targets of a polypharmacological drug from variations in the responsed networks in thedfferentiated populations with complex diseases,as stable coronary heart ***,in an adaptive,31-center,randomized,double-blind trial invoving 920 patients with moderate symptomatic stable angina treated by 14-day Danhong injection(DHI),a kind of polyphamacological drug with high quality control,or placebo(0.9%saline),with 76-day following-up,we firstly confrmed that DHl couldincrease the proportion of patients with clinically significant changes on angina-frequency assessed by Seattle Angina Questionnaire(ASAQ-AF220)(12.78%at Day 30,95%confidence interval[C]5.86-19.71%,P=0.0003,13.82%at Day 6C0,95%CI 6.82-20.82%,P=0.0001and 8.95%at Day 90,95%CI 2.06-15.85%,P=0.01).We also found that there were no significant differences in new-onset major vascularevents(P=0.8502)and serious adverse events(P=0.9105)between DHl and *** performing the RNA sequencing in 62 selectedpatients,we developed a systemic modular approach tp identfy differentilly expressed modules(DEMs)of DHI with the Z_(summay)valueless than 0 compared with the control group,calculated by weighted gene co-expression network analysis(WGCNA),and sketched out thebasic framework on a modular map with 25 functional modules targeted by ***,the effective therapeutic module(ETM),defined as the highest corelation value with the phenotype alteration(SAQ-AF,the change in SAQ-AF at Day 30 from baseline)calculatedby WGCNA,was identifed in the population with the best effect(ASAQ-AF240),which is related to anticoagulation and regulation ofcholesterol *** assessed the modular flexbility of this ETM using the global topological D value based on Euclidean distance,which is corelated with phenotype alteration(r^(2):0.8204,P=0.019)by linear *** study identified the ant-angina therapeuticmodule in the effective population treated by the multi-target

关键词： angina injection sketch

An-Luo-Hua-Xian Pill Improves the Regression of liver Fibrosis in Chronic Hepatitis B Patients Treated with Entecavir

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Journal of Clinical and Translational Hepatology 2023年第2期11卷 304-313页

作者： yi-Qi liu Chi Zhang Jia-Wen li li-Hua Cao Zhan-qing Zhang Wei-feng Zhao qing-Hua Shang Da-Zhi Zhang An-lin Ma qing Xie Hong-lian Gui Guo Zhang ying-Xia liu Jia Shang Shi-Bin Xie Jun li Xu-qing Zhang Zhi-Qiang Zou yu-ping chen Zong Zhang ming-xiang Zhang Jun cheng Fu-Chun Zhang li-Hua Huang Jia-Bin li qing-Hua Meng Hai-Bin yu yu-Qiang mi Yan-Zhong Peng Zhi-Jin wang li-ming chen Fan-ping Meng Wan-Hua Ren Lang Bai yi-Lan Zeng Rong Fan Xian-Zhi Lou Wei-feng liang Hui liu Hui Zhuang Hong Zhao Gui-Qiang wang Department of Infectious Disease Center for Liver DiseasePeking University First HospitalBeijingChina Department of Hepatology The Third Hospital of QinhuangdaoQinhuangdaoHebeiChina Department of Infectious Disease Shanghai Public Health Clinical CenterFudan UniversityShanghaiChina Department of Infectious Disease Xinxiang Medical University Affiliated Third HospitalXinxiangHenanChina No.88 Hospital of Chinese People’s liberation Army(PLA) JinanShandongChina Department of Infectious Diseases The Second Affiliated Hospital of Chongqing Medical UniversityChongqingChina Department of Infectious Disease China-Japan Friendship HospitalBeijingChina Department of Infectious Diseases Ruijin HospitalSchool of MedicineShanghai Jiaotong UniversityShanghaiChina Department of Gastroenterology The People’s Hospital of Guangxi Zhuang Autonomous RegionNanningGuangxiChina Department of Infectious Diseases The Third People’s Hospital of ShenzhenShenzhenGuangdongChina Department of Infectious Diseases The People’s Hospital of Henan ProvinceZhengzhouHenanChina Department of Infectious Disease The Third Affiliated Hospital of Sun-Yat Sen UniversityGuangzhouGuangdongChina Department of Infectious Diseases Jiangsu Province HospitalThe First Affiliated Hospital of Nanjing Medical UniversityNanjingJiangsuChina Department of Infectious Diseases The Southwest Hospital of Army Medical UniversityChongqingChina Yantai Infectious Diseases Hospital YantaiShandongChina Department of Hepatology Baoding Infectious Diseases HospitalBaodingHebeiChina Department of Integrated Traditional Chinese Medicine(TCM)and Western Medicine Jinan Infectious Diseases HospitalShandong UniversityJinanShandongChina Department of Integrated TCM and Western Medicine in Hepatology The Sixth People’s Hospital of ShenyangShenyangLiaoningChina Beijing Ditan Hospital Capital Medical UniversityBeijingChina Department of Infectious Diseases Guangzhou Eighth People’s HospitalGuangzhou Medical UniversityGuangzhouGuangdon

Background and Aims:Chronic hepatitis B(CHB)can cause liver fibrosis and lead to cirrhosis and *** the effectiveness of antiviral therapy to reverse liver fibrosis is limited,We aimed to evaluate the effect of An-Luo-Hua-Xian pill(ALHX)on fibrosis regression in CHB patients treated with entecavir(ETV).Methods:Treatment-naïve patients with CHB were randomly treated with ETV alone or combined with ALHX(ETV+ALHX)between October 1,2013 and December 31,***,laboratory,and liver histology data before and after 78 weeks of treatment were *** Ishak fibrosis score(F)was used and fibrosis regression required a decrease in F of≥1 after ***:A total of 780 patients were enrolled,and 394 with a second liver biopsy after treatment were included in the per-protocol population,132 in ETV group and 262 in ETV+ALHX *** 78 weeks of treatment,the fibrosis regression rate in the ETV+ALHX group was significantly higher than that of the ETV group at baseline F≥3 patients:124/211(58.8%)vs.45/98(45.9%),p=*** percentage of patients with a decreased liver stiffness measurement(LSM)was higher in the ETV+ALHX group:156/211(73.9%)vs.62/98(63.%),p=*** regression analysis showed that ETV combined with ALHX was associated with fibrosis regression[odds ratio(OR)=1.94,p=0.018],and a family history of hepatocellular carcinoma was on the contrary.(OR=0.41,p=0.031).Conclusions:ETV combined with ALHX increased liver fibrosis regression in CHB patients.

关键词： Chronic hepatitis B liver fibrosis Regression Randomized controlled trial

Association of Overlapped and Un-overlapped Comorbidities with COVID-19 Severity and Treatment Outcomes: A Retrospective Cohort Study from Nine Provinces in China

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Biomedical and Environmental Sciences 2020年第12期33卷 893-905页

作者： MA Yan ZHU dong Shan chen Ren Bo SHI Nan Nan liu Si Hong FAN yi Pin WU Gui Hui YANG Pu Ye BAI Jiang feng chen Hong chen li ying feng Qiao GUO Tuan Mao HOU Yong HU Gui Fen HU xiao Mei HU yun Hong HUANG Jin HUANG Qiu Hua HUANG Shao Zhen JI liang JIN Hai Hao LEI xiao li Chun Yan li min qing li Qun Tang li Xian Yong liu Hong De liu Jin ping liu Zhang MA yu Ting MAO Ya MO liu Fen NA Hui wang Jing Wei SONG Fang li suN Sheng wang dong Ting wang ming Xuan wang xiao Yan wang yin Zhen wang yu dong WU Wei WU Lan ping xiao Yan Hua XIE Hai Jun XU Hong ming XU Shou Fang XUE Rui Xia YANG Chun YANG Kai Jun yuAN Sheng li ZHANG Gong Qi ZHANG Jin Bo ZHANG lin Song ZHAO Shu Sen ZHAO Wan ying ZHENG Kai ZHOU ying Chun ZHU Jun Teng ZHU Tian qing ZHANG Hua min wang Yan ping wang Yong Yan 无 Institute of Basic Research in Clinical Medicine China Academy of Chinese Medical SciencesBeijing 100700China Centre for Health Management and Policy Research School of Public HealthCheeloo College of MedicineShandong UniversityJinan 250012ShandongChina Institute of Information on Traditional Chinese Medicine China Academy of Chinese Medical SciencesBeijing 100700China Department of Tuberculosis The Public Health Clinical Center of ChengduChengdu 610066SichuanChina Department of Infectious Disease Shaanxi Infectious Disease HospitalXi'an 610113ShaanxiChina Department of Infectious Disease Yulin Chinese Medicine HospitalYulin 719000ShaanxiChina President's Office The First Hospital of QiqiharQiqihar 161005HeilongjiangChina Department of Traditional Chinese Medicine Shangluo Central HospitalShangluo 726000ShaanxiChina Department of Traditional Chinese Medicine The People's Hospital of QitaiheQitaihe 154603HeilongjiangChina Department of Scientific Research Xianyang Central HospitalXianyang 712000ShaanxiChina Department of traditional Chinese medicine The First Affiliated Hospital of Anhui University of Traditional Chinese MedicineHefei 230012AnhuiChina Department of Infectious Disease Heping Hospital Affiliated to Changzhi Medical CollegeChangzhi 046000ShanxiChina Department of Traditional Chinese Medicine Langfang Hospital of Chinese MedicineLangfang 065000HeibeiChina Department of Traditional Chinese Medicine Xingtai Hospital of Chinese MedicineXingtai 054001HeibeiChina Department of Traditional Chinese Medicine The People's Hospital of Guangxi Zhuang Autonomous RegionNanning 168600GuangxiChina Department of Traditional Chinese Medicine The First People'sHospital of FangchenggangFangchenggang 538001GuangxiChina Department of Traditional Chinese Medicine Mianyang Hospital of Traditional Chinese MedicineMianyang 621000SichuanChina Department of Traditional Chinese Medicine Liuzhou People's HospitalLiuzhou 545006GansuChina Department of Traditional Chinese Medici

Objective Several COVID-19 patients have overlapping comorbidities. The independent role of each component contributing to the risk of COVID-19 is unknown, and how some non-cardiometabolic comorbidities affect the risk of COVID-19 remains *** A retrospective follow-up design was adopted. A total of 1,160 laboratory-confirmed patients were enrolled from nine provinces in China. Data on comorbidities were obtained from the patients’ medical records. Multivariable logistic regression models were used to estimate the odds ratio(OR) and 95% confidence interval(95% CI) of the associations between comorbidities(cardiometabolic or non-cardiometabolic diseases), clinical severity, and treatment outcomes of *** Overall, 158(13.6%) patients were diagnosed with severe illness and 32(2.7%) had unfavorable outcomes. Hypertension(2.87, 1.30–6.32), type 2 diabetes(T2 DM)(3.57, 2.32–5.49),cardiovascular disease(CVD)(3.78, 1.81–7.89), fatty liver disease(7.53, 1.96–28.96), hyperlipidemia(2.15, 1.26–3.67), other lung diseases(6.00, 3.01–11.96), and electrolyte imbalance(10.40, 3.00–26.10)were independently linked to increased odds of being severely ill. T2 DM(6.07, 2.89–12.75), CVD(8.47,6.03–11.89), and electrolyte imbalance(19.44, 11.47–32.96) were also strong predictors of unfavorable outcomes. Women with comorbidities were more likely to have severe disease on admission(5.46,3.25–9.19), while men with comorbidities were more likely to have unfavorable treatment outcomes(6.58, 1.46–29.64) within two *** Besides hypertension, diabetes, and CVD, fatty liver disease, hyperlipidemia, other lung diseases, and electrolyte imbalance were independent risk factors for COVID-19 severity and poor treatment outcome. Women with comorbidities were more likely to have severe disease, while men with comorbidities were more likely to have unfavorable treatment outcomes.

关键词： Comorbidities COVID-19 Severity Gender Age Treatment outcome

Efficacy and safety of Shenyankangfu Tablet,a Chinese patent medicine,for primary glomerulonephritis:A multicenter randomized controlled trial

在线全文

学校读者我要写书评

暂无评论

Journal of Integrative Medicine 2021年第2期19卷 111-119页

作者： Jie Wu Shu-wei Duan Hong-tao Yang yue-yi Deng Wei li Ya-ni He Zhao-hui Ni Yong-li Zhan Shan lin Zhi-yong Guo Jun Zhu Jing-ai Fang Xu-sheng liu li-hua wang Rong wang Nian-song wang xiao-hong cheng li-qun He ping Luo Shi-ren sun Ji-feng sun Ai-ping yin Geng-ru Jiang Hong-yu chen Wen-hu liu Hong-li lin Meng liang Lu Ma ming chen li-qun Song Jian chen qing Zhu Chang-ying Xing yun li Ji-ning Gao Rong-shan li ying li Hao Zhang ying Lu Qiao-ling Zhou Jun-zhou Fu Qiang He Guang-yan Cai xiang-mei chen Department of Nephrology Chinese People’s Liberation Army General HospitalChinese People’s Liberation Army Institute of NephrologyState Key Laboratory of Kidney Diseases(2011DAV00088)National Clinical Research Center for Kidney DiseasesBeijing 100853China Department of Nephrology First Teaching Hospital of Tianjin University of Traditional Chinese MedicineTianjin 300192China Department of Nephrology Longhua HospitalShanghai University of Traditional Chinese MedicineShanghai 200032China Department of Nephrology Shandong University of Traditional Chinese Medicine Affiliated HospitalJinan 250011.Shandong ProvinceChina Department of Nephrology Daping HospitalArmy Medical UniversityChongqing 400042China Department of Nephrology Renji HospitalShanghai Jiao Tong UniversityShanghai 200127China Department of Nephrology Guang’anmen HospitalChina Academy of Traditional Chinese Medical SciencesBeijing 100053China Department of Nephrology Tianjin Medical University General HospitalTianjin 300052China Department of Nephrology Changhai Hospital of ShanghaiNaval Medical UniversityShanghai 200433China Department of Nephrology West China HospitalChengdu 610083Sichuan ProvinceChina Department of Nephrology First Affiliated Hospital of Shanxi Medical UniversityTaiyuan 030001Shanxi ProvinceChina Department of Nephrology Guangdong Provincial Hospital of Chinese MedicineGuangzhou 510120Guangdong ProvinceChina Department of Nephrology Shanxi Medical University Second Affiliated HospitalTaiyuan 030001Shanxi ProvinceChina Department of Nephrology Shandong Provincial HospitalJinan 250021Shandong ProvinceChina Department of Nephrology and Rheumatology Affiliated Sixth People’s HospitalShanghai Jiao Tong UniversityShanghai 200233China Department of Nephrology Shaanxi Traditional Chinese Medicine HospitalXi'an 710003Shaanxi ProvinceChina Department of Nephrology Shuguang HospitalShanghai University of Traditional Chinese MedicineShanghai 200021China Department of Nephrology Jilin University Se

Background:Shenyankangfu Tablet(SYKFT)is a Chinese patent medicine that has been used widely to decrease proteinuria and the progression of chronic kidney ***:This trial compared the efficacy and safety of SYKFT,for the control of proteinuria in primary glomerulonephritis patients,against the standard drug,losartan ***,setting,participants and intervention:This was a multicenter,double-blind,randomized,controlled clinical *** glomerulonephritis patients,aged 18-70 years,with blood pressure≤140/90 mmHg,estimated glomerular filtration rate(eGFR)>45 mL/min per 1.73 ㎡,and 24-hour proteinuria level of 0.5-3.0 g,were recruited in 41 hospitals across 19 provinces in China and were randomly divided into five groups:SYKFT,losartan potassium 50 mg or 100 mg,SYKFT plus losartan potassium 50 mg or 100 *** outcome measu res:The primary outcome was change in the 24-hour proteinuria level,after 48 weeks of ***:A total of 735 participants were *** percent decline of urine protein quantification in the SYKFT group after 48 weeks was 8.78%±2.56%(P=0.006)more than that in the losartan 50 mg group,which was 0.51%±2.54%(P=1.000)less than that in the losartan 100 mg *** with the losartan potassium 50 mg group,the SYKFT plus losartan potassium 50 mg group had a 13.39%±2.49%(Psuperiority threshold of 15%,neither was statistically ***,serum creatinine and serum albumin from the baseline did not change statistically *** average change in TCM syndrome score between the patients who took SYKFT(-3.00[-6.00,-2.00])and who did not take SYKFT(-2.00[-5.00,0])was statistically significant(P=0.003).No obvious adverse reactions were observed in any ***:SYKFT decreased the proteinur

关键词： Herbal medicine,Chinese Shenyankangfu Tablet Primary glomerulonephritis Randomized controlled trial Double blind Double dummy

Measurement of the neutron total cross section of carbon at the Back-n white neutron beam of CSNS

在线全文

学校读者我要写书评

暂无评论

Nuclear Science and Techniques 2019年第9期30卷 73-82页

作者： Xing-Yan liu yi-Wei Yang Rong liu Jie Wen Zhong-Wei Wen Zi-Jie Han Zhi-Zhou Ren Qi An Huai-Yong Bai Jie Bao ping Cao Qi-ping chen Yong-Hao chen Pin-Jing cheng Zeng-Qi Cui Rui-Rui Fan Chang-qing feng min-Hao Gu feng-Qin Guo Chang-Cai Han Guo-Zhu He Yong-cheng He yue-feng He Han-Xiong Huang Wei-ling Huang Xi-Ru Huang xiao-Lu Ji Xu-Yang Ji Hao-yu Jiang Wei Jiang Han-Tao Jing ling Kang ming-Tao Kang Bo li Lun li Qiang li xiao li Yang li Yang li Shu-Bin liu Guang-yuan Luan ying-lin Ma Chang-Jun Ning Bin-Bin Qi Jie Ren Xi-Chao Ruan Zhao-Hui Song Hong sun xiao-Yang sun Zhi-Jia sun Zhi-Xin Tan Hong-qing Tang Jing-yu Tang Peng-cheng wang Qi wang Tao-feng wang Yan-feng wang Zhao-Hui wang Zheng wang qing-Biao Wu xiao-Guang Wu Xuan Wu li-Kun Xie Han yi li yu Tao yu Yong-Ji yu Guo-Hui Zhang Jing Zhang lin-Hao Zhang li-ying Zhang qing-min Zhang Qi-Wei Zhang Xian-Peng Zhang yu-liang Zhang Zhi-Yong Zhang ying-Tan Zhao liang Zhou Zu-ying Zhou Dan-Yang Zhu Ke-Jun Zhu Peng Zhu Institute of Nuclear Physics and Chemistry China Academy of Engineering Physics State Key Laboratory of Particle Detection and Electronics Chinese Academy of Sciences(CAS) Department of Modern Physics University of Science and Technology of China State Key Laboratory of Nuclear Physics and Technology School of PhysicsPeking University Key Laboratory of Nuclear Data China Institute of Atomic Energy Institute of High Energy Physics Chinese Academy of Sciences(CAS) Spallation Neutron Source Science Center University of South China Northwest Institute of Nuclear Technology Department of Engineering and Applied Physics University of Science and Technology of China Beihang University Xi’an Jiaotong University

To verify the performance of the neutron total cross-sectional spectrometer, the neutron total cross section of carbon is initially measured in the energy range of 1 eV to 20 MeV using the time-of-flight method. The measurement is performed at the Back-n white neutron source with a 76-m time-of-flight path using the China Spallation Neutron Source. A multilayer fast fission chamber with 235U and 238U is employed as the neutron detector. The diameter and thickness of the natural graphite sample are 70 mm and 40 mm, respectively. Signal waveforms are collected using a data acquisition system. Off-line data processing was used to obtain the neutron time-of-flight spectra and transmissions. The uncertainty of the counting statistics is generally approximately 3% for each bin in the energy range of 1–20 MeV. It is determined that the results for the neutron total cross section of carbon obtained using ^235U cells are in good agreement with the results obtained using 238U cells within limits of statistical uncertainty. Moreover, the measured total cross sections show good agreement with the broadening evaluated data.

关键词： CSNS Back-n white neutron source NTOX Neutron total cross section Carbon Multilayer fast fission chamber

Chemoprophylaxis, diagnosis, treatments, and discharge management of COVID-19: An evidence-based clinical practice guideline(updated version)

在线全文

学校读者我要写书评

暂无评论

military Medical Research 2020年第3期7卷 249-282页

作者： ying-Hui Jin qing-yuan Zhan Zhi-Yong Peng Xue-Qun Ren Xun-Tao yin lin Cai yu-feng yuan Ji-Rong yue xiao-Chun Zhang Qi-Wen Yang Jianguang Ji Jian Xia yi-Rong li Fu-xiang Zhou Ya-dong Gao Zhui yu feng Xu ming-li Tu li-ming Tan min Yang Fang chen xiao-Ju Zhang Mei Zeng yu Zhu Xin-Can liu Jian Yang dong-Chi Zhao yu-feng Ding Ning Hou Fu-Bing wang Hao chen Yong-Gang Zhang Wei li Wen chen yue-Xian Shi Xiu-Zhi Yang Xue-Jun wang Yan-Jun Zhong ming-Juan Zhao Bing-Hui li lin-Lu Ma Hao Zi Na wang yun-yun wang Shao-Fu yu Lu-Yao li Qiao Huang Hong Weng xiang-ying Ren li-Sha Luo Man-Ru Fan Di Huang Hong-Yang Xue lin-Xin yu Jin-ping Gao Tong Deng Xian-Tao Zeng Hong-Jun li Zhen-Shun cheng xiao-Mei Yao Xing-Huan wang Center for Evidence-Based and Translational Medicine Zhongnan Hospital of Wuhan UniversityWuhan 430071China National Clinical Research Center for Respiratory Diseases China-Japan Friendship HospitalBeijing 100029China Department of Pulmonary and Critical Care Medicine China-Japan Friendship HospitalBeijing 10029China Leishenshan Hospital in Wuhan Wuhan 430200China Department of Critical Care Medicine Zhongnan Hospital of Wuhan UniversityWuhan 430071China Institutes of Evidence-based Medicine and Knowledge Translation Henan UniversityKaifeng 475000HenanChina Department of Medical Imaging Guizhou Provincial People’s HospitalGuiyang 550002China Departments of Orthopedics Zhongnan Hospital of Wuhan UniversityWuhan 430071China Department of Hepatobiliary surgery Zhongnan Hospital of Wuhan UniversityWuhan 430071China National Clinical Research Center for Geriatrics West China Hospital of Sichuan UniversityChengdu 610041China Department of Geriatrics West China Hospital of Sichuan UniversityChengdu 610041China Department of Radiology Zhongnan Hospital of Wuhan UniversityWuhan 430071China Department of Clinical Laboratory Peking Union Medical College Hospital(PUMCH)Peking Union Medical CollegeChinese Academy of Medical Sciences(CAMS)Beijing 100730China Center for Primary Health Care Research Lund University and Region Skåne25002 MalmöSweden Emergency Center Zhongnan Hospital of Wuhan UniversityWuhan 403371China Department of Allergology Zhongnan Hospital of Wuhan UniversityWuhan 430071China Department of Radiation and Medical Oncology Zhongnan Hospital of Wuhan UniversityWuhan 43071China Department of Critical Care Medicine Renmin Hospital of Wuhan UniversityWuhan 430060China Department of Emergency Medicine and Chest Pain Center Qilu Hospital of Shandong UniversityJinan 250002China Department of Respiratory and Critical Care Medicine Suizhou Central HospitalHubei University of MedicineSuizhou 441300HubeiChina Department of Clinic Pharmacy Second People’s Hospital of Huaihua Ci

The novel severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)is the cause of a rapidly spreading illness,coronavirus disease 2019(COVID-19),affecting more than seventeen million people around the *** and treatment guidelines for clinicians caring for patients are *** the early stage,we have issued"A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus(2019-nCoV)infected pneumonia(standard version)";now there are many direct evidences emerged and may change some of previous recommendations and it is ripe for develop an evidence-based *** formed a working group of clinical experts and *** steering group members proposed 29 questions that are relevant to the management of COVID-19 covering the following areas:chemoprophylaxis,diagnosis,treatments,and discharge *** searched the literature for direct evidence on the management of COVID-19,and assessed its certainty generated recommendations using the Grading of Recommendations,Assessment,Development and Evaluation(GRADE)*** were either strong or weak,or in the form of ungraded consensus-based ***,we issued 34 *** them,6 were strong recommendations for,14 were weak recommendations for,3 were weak recommendations against and 11 were ungraded consensus-based *** covered topics of chemoprophylaxis(including agents and Traditional Chinese Medicine(TCM)agents),diagnosis(including clinical manifestations,reverse transcription-polymerase chain reaction(RT-PCR),respiratory tract specimens,IgM and IgG antibody tests,chest computed tomography,chest X-ray,and CT features of asymptomatic infections),treatments(including lopinavirritonavir,umifenovir,favipiravir,interferon,remdesivir,combination of antiviral drugs,hydroxychloroquine/chloroquine,interleukin-6 inhibitors,interleukin-1 inhibitors,glucocorticoid,qingfei paidu decoction,lianhua qingwen granules/capsules,convalescent plasma,lung

关键词： COVID-19 SARS-CoV-2 Recommendation Chemoprophylaxis Diagnosis Treatment Discharge management Traditional Chinese medicine guideline